TICKERNERD
Menu
PODDPODDHealthcare · Medical Devices

PODD Stock Forecast: Insulet Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$141
−0.67% on the day

The 25 Wall Street analysts covering Insulet Corp. hold a median 12-month price target of $168 — +19.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.8B
Ticker Nerd rank
89 / 100
Median analyst target
$168
Analysts covering
25
Free cash flow$51.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.5%
1M
−5.0%
YTD
−50.5%
1Y
−57.8%
From 52W high
−59.4%
From 52W low
+6.5%
$132
$346
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PODD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Insulet Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Value
96
Volatility
96
Quality
94
Growth
83
Revisions
71
Accruals
57
Size
16
Momentum
9

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PODD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PODD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350Oct 25Jan 26Apr 26Jul 26PODDHigh $275Median $168Low $144

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says25 analysts
15 Buy10 Hold0 Sell
Low $144Median $168High $275

The green dot is the last close — the median target sits +19.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 14 moved it down.

DateFirmActionRatingTarget
6 Aug 2026BenchmarkMaintainsBuy$250 → $185
6 Aug 2026BernsteinMaintainsOutperform$200 → $175
6 Aug 2026BTIGDowngradeNeutral—
6 Aug 2026Canaccord GenuityMaintainsBuy$249 → $179
6 Aug 2026JP MorganDowngradeNeutral$275 → $152
6 Aug 2026Leerink PartnersDowngradeMarket Perform$247 → $145
6 Aug 2026RBC CapitalMaintainsOutperform$245 → $160
6 Aug 2026StifelMaintainsBuy$225 → $180
6 Aug 2026TD CowenMaintainsHold$294 → $144
6 Aug 2026Truist SecuritiesDowngradeHold$210 → $153
6 Aug 2026UBSMaintainsNeutral$174 → $150
6 Aug 2026Wells FargoDowngradeEqual-Weight$255 → $144
28 July 2026UBSAssumesNeutral$174
13 July 2026RBC CapitalMaintainsOutperform$280 → $245
13 July 2026RBC CapitalMaintainsOutperform—
13 July 2026Truist SecuritiesMaintainsBuy$219 → $210
13 July 2026Truist SecuritiesMaintainsBuy—
10 July 2026StifelMaintainsBuy$250 → $225
10 July 2026StifelMaintainsBuy—
8 July 2026CitigroupMaintainsNeutral$165 → $172

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PODD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PODD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Insulet Corp. returned −57.8% against +16.3% for the S&P 500, dividends included.

PODD vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26PODDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PODD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.3%
Analysts raising
15
Analysts cutting
7
Fundamentals

Insulet Corp. (PODD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.4×

Cheaper than 29% of US stocks

Price / sales
3.2×

Cheaper than 39% of US stocks

Price / book
6.9×

Cheaper than 14% of US stocks

EV / EBITDA
16.5×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
23.5%

Higher than 73% of US stocks

Earnings growth (YoY)
322.2%

Higher than 93% of US stocks

Gross margin
70.2%

Higher than 83% of US stocks

Operating margin
16.2%

Higher than 74% of US stocks

Net margin
12.3%

Higher than 74% of US stocks

Returns & dividend
Return on equity
26.0%

Higher than 86% of US stocks

Return on assets
9.7%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Insulet Corp. (PODD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Insulet Corp. has a market value of $9.8B and an enterprise value of $10.2B.

  • Diluted earnings per share, trailing twelve months: $5.35.

  • Free cash flow in the twelve months to 30 June 2026: $265.6M, after $217.5M of capital spending.

  • Insulet Corp. spent $329.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 69.4M.

  • Trailing P/E: 26.4×; forward P/E: 18.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Insulet Corp. employs 5,400 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

PODD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PODDInsulet Corp.$9.8B
89
GKOSGlaukos Corp.$9.7B
92
GMEDGlobus Medical, Inc.$9.9B
96
TXG10X Genomics, Inc.$10.0B
94
BIOBio-Rad Laboratories, Inc.$10.1B
90
BRKRBruker Corp.$9.3B
87
PENPenumbra, Inc.$12.5B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Insulet Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PODD news & analysis

Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

Business Wire · 18 Sept 2026neutral

Insulet Corporation announced that its management will present at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 24, 2026, at 12:30 p.m. Eastern Time. A live webcast and replay will be available via the Insulet Investor Relations website.

Why it matters — This gives Insulet shareholders and followers an opportunity to hear directly from management about the company at a notable healthcare investor forum.

Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Insulet Corporation presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the event published by Seeking Alpha. The presentation covers the company's remarks and discussion at the conference.

Why it matters — PODD watchers can review management's commentary at a major healthcare investor conference for insight into the company's current positioning and outlook.

Here's Why Insulet (PODD) is a Strong Growth Stock

Zacks Investment Research · 9 Sept 2026positive

Zacks Investment Research highlights Insulet (PODD) as a strong growth stock. The article references the Zacks Style Scores system, which helps investors identify top-rated stocks based on their investing style.

Why it matters — A PODD watcher would care because the piece signals that Insulet ranks well on Zacks' growth-oriented scoring criteria.

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Zacks Investment Research · 8 Sept 2026positive

Zacks notes that Insulet's Omnipod 5 adoption, product expansion, and raised international growth outlook support its growth prospects, despite competitive and cost pressures. The piece evaluates whether it is prudent to retain the stock in a portfolio.

Why it matters — PODD watchers would care because the item highlights the drivers behind Insulet's growth outlook and the competitive and cost challenges it currently faces.

Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 7 Sept 2026positive

Zacks Investment Research reports that Insulet (PODD) is a top-ranked value stock according to its Style Scores system, which helps investors identify highly rated stocks based on investing style.

Why it matters — PODD watchers would care because the stock's top value ranking may influence how investors view the company's investment profile.

FAQ

Frequently asked questions about PODD stock

What is the PODD stock price forecast for 2026-2027?

The 25 Wall Street analysts covering Insulet Corp. have a median 12-month price target of $168, with estimates ranging from $144 to $275. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PODD stock a buy right now?

Of the 25 analysts covering Insulet Corp., 15 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Insulet Corp. 89 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PODD?

As at 19 Sept 2026, Insulet Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will PODD stock go up?

No one can know that. What the data says: the median 12-month target from 25 analysts implies +19.1% from the last close, and Ticker Nerd's factor model ranks Insulet Corp. 89 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PODD stock forecast for 2030?

No analyst covering Insulet Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PODD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $144 to $275 over the next 12 months.

How has PODD stock performed over the past year?

Insulet Corp. returned -57.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Insulet Corp. do?

Insulet Corporation is a medical device company focused on insulin delivery and diabetes management. Its flagship Omnipod platform includes wearable, tubeless insulin management systems designed to deliver continuous insulin without traditional pump tubing or multiple daily injections.

What is the latest news on PODD?

The most recent item we track (Business Wire, 18 Sept 2026): "Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum". Insulet Corporation announced that its management will present at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 24, 2026, at 12:30 p.m. Eastern Time. A live webcast and replay will be available via the Insulet Investor Relations website.

Company

About Insulet Corp.

Insulet Corporation is a medical device company focused on insulin delivery and diabetes management. Its flagship Omnipod platform includes wearable, tubeless insulin management systems designed to deliver continuous insulin without traditional pump tubing or multiple daily injections. The product line includes Omnipod 5, Omnipod DASH, and the Classic Omnipod, along with related pods, controllers, and diabetes management software that support day-to-day glucose control. Insulet also works with selected partners to adapt its Pod technology for the subcutaneous delivery of non-insulin therapies in other medical areas. Headquartered in Acton, Massachusetts, Insulet serves patients and healthcare providers across multiple international markets through direct sales and distribution channels.

CEO Ms. Ashley A. McEvoy · 5,400 employees · United States · https://www.insulet.com